| Stage | AVGO | % of rev | ABBV | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $29.6B | 100.00% | $17.4B | 100.00% | AVGO ×1.70 |
| Gross profit | $20.5B | 69.13% | $12.9B | 74.14% | ABBV +5.0pp |
| Operating income | $16.0B | 53.92% | $6.3B | 36.01% | AVGO +17.9pp |
| Pre-tax income | $15.3B | 51.62% | $4.8B | 27.75% | AVGO +23.9pp |
| Net income | $13.1B | 44.23% | $4.2B | 24.25% | AVGO +20.0pp |
| Stage | AVGO | ABBV | Gap · A − B |
|---|---|---|---|
| Revenue | $29.6B100.00% | $17.4B100.00% | AVGO ×1.70 |
| Gross profit | 69.13%$20.5B | 74.14%$12.9B | ABBV +5.0pp |
| Operating income | 53.92%$16.0B | 36.01%$6.3B | AVGO +17.9pp |
| Pre-tax income | 51.62%$15.3B | 27.75%$4.8B | AVGO +23.9pp |
| Net income |
| 44.23%$13.1B |
| 24.25%$4.2B |
| AVGO +20.0pp |
No shared counterparties.